Products

Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
PLK1 protein kinase inhibitor BI 2536, 2 mg  

PLK1 protein kinase inhibitor BI 2536, 2 mg

4-((R)-8-Cyclopentyl-7-ethyl-5-methyl-6-oxo-5,6,7,8-tetrahydro-pteridin-2-ylamino)-3-methoxy-N-(1-methyl-piperidin-4-yl)-benzamide

BI 2536 is a potent and selective polo-like kinase (PLK) 1 inhibitor.

More details

PKI-BI2536-002

Availability: within 3 days

97,50 €

Background: BI 2536 is a potent and selective polo-like kinase (PLK) 1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3.

Chemical formula: C28H39N7O3
Molecular weight: 521.65 g/mol
Purity: 99 %
Appearance: White solid
Solubility: Soluble in DMSO
CAS Number: 755038-02-9

Manufacturer:  Axon Medchem BV

PLEASE NOTE: This product is designed for research purposes and can only be delivered to academic and business customers.  

References

M Steegmaier et al. BI 2536, a Potent and Selective Inhibitor of Polo-like Kinase 1, Inhibits Tumor Growth In Vivo. Curr Biol 2007, 17, 316-322.
 
P Lénárt et al. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1. Curr Biol 2007, 17(4), 304-15.
 
M Sebastian et al. The Efficacy and Safety of BI 2536, a Novel Plk-1 Inhibitor, in Patients with Stage IIIB/IV Non-small Cell Lung Cancer Who Had Relapsed after, or Failed, Chemotherapy. J. Thor. Oncol. 2010, 5(7), 1060-1067.
 
HJ Stewart et al. The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma. Exp. Hematol. 2011, 39(3), 330-338.